Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice.

European journal of clinical pharmacology - 1 May 2021

Russmann Stefan, Rahmany Ali, Niedrig David, Hatz Karl-Dietrich, Ludin Katja, Burden Andrea M, Englberger Lars, Backhaus Roland, Serra Andreas, Béchir Markus

Abstract excerpt

PURPOSE: The antiplatelet prodrug clopidogrel is bioactivated by the polymorphic enzyme CYP2C19. Prospective clinical studies demonstrated an association between CYP2C19 loss of function (LoF) variants and an increased risk of thrombotic events under clopidogrel, but pharmacogenetic (PGx) testing is not frequently implemented in clinical practice. We report our experience with PGx-guided clopidogrel therapy with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Disease Risk Factors

Share to Ischemia

Share to Pharmacogenomic Testing

Share to Platelet Aggregation Inhibitors

Share to Precision Medicine

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 33242107
DOI: 10.1007/s00228-020-03050-4
PMCID: PMC8032605

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice.PMID 33242107Read ↗

Real-World Implementation of CYP2C19 Pharmacogenetic Testing in Clopidogrel-Treated Patients: Insights from French Clinical DataSemantic proximity Read ↗

Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative.Semantic proximity Read ↗

Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Semantic proximity Read ↗

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.Semantic proximity Read ↗

Genetic variation in activating clopidogrel: longer-term outcomes in a large community cohortSemantic proximity Read ↗

Analysis of CYP2C19 genetic variants with ischaemic events in UK patients prescribed clopidogrel in primary care: a retrospective cohort study.Semantic proximity Read ↗

Clinical Outcomes and Sustainability of Using CYP2C19 Genotype–Guided Antiplatelet Therapy After Percutaneous Coronary InterventionSemantic proximity Read ↗

CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.Semantic proximity Read ↗

Antiplatelet therapy guided by CYP2C19 point-of-care pharmacogenetics plus multidimensional treatment decisions.Semantic proximity Read ↗

Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis.Semantic proximity Read ↗

Implementation of clopidogrel pharmacogenetics: a Brazilian perspective.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.